16839-98-8

Basic information

• Product Name: Noratropine
• Synonyms: Noratropine;Benzeneacetic acid, alpha-(hydroxymethyl)-, (3-endo)-8-azabicyclo(3.2.1)oct-3-yl ester;Benzeneacetic acid, alpha-(hydroxymethyl)-, 8-azabicyclo(3.2.1)oct-3-yl ester, endo-(+-)-;1αH,5αH-Nortropan-3α-ol, (+/-)-Tropate Ester;N-DeMethylatropine;α-(HydroxyMethyl)benzeneacetic Acid (3-endo)-8-Azabicyclo[3.2.1]oct-3-yl Ester
• CAS NO: 16839-98-8
• Molecular Formula: C₁₆H₂₁NO₃
• Molecular Weight: 275.34284
• Product Categories: Aroamtics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 16839-98-8.mol
• Article Data: 12

Chemical Properties

• Melting Point: 113-114 °C
• Boiling Point: 440.2°Cat760mmHg
• Flash Point: 220°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 1.97E-09mmHg at 25°C
• Refractive Index: 1.583
• PKA: 14.12±0.10(Predicted)
• CAS DataBase Reference: Noratropine(CAS DataBase Reference)
• NIST Chemistry Reference: Noratropine(16839-98-8)
• EPA Substance Registry System: Noratropine(16839-98-8)

Safety Data

• Hazardous Substances Data: 16839-98-8(Hazardous Substances Data)

Usage

Description

Noratropine, a metabolite of Atropine (A794625), is derived from the chemical breakdown of Atropine in the body. It is one of the two metabolites, along with apoatropine, that have been identified in rat urine. Noratropine possesses unique chemical properties that make it a potential candidate for various applications across different industries.

Uses

Used in Pharmaceutical Industry:
Noratropine is used as an active pharmaceutical ingredient for its potential therapeutic effects. As a metabolite of Atropine, it may exhibit similar or distinct pharmacological properties that can be harnessed for the development of new drugs or therapies.
Used in Research and Development:
In the field of scientific research, Noratropine is used as a subject of study to better understand the metabolic pathways of Atropine and its potential effects on the human body. This knowledge can contribute to the development of more effective drugs and treatments.
Used in Toxicology Studies:
Noratropine is used as a biomarker in toxicology studies to assess the exposure to Atropine or related compounds. Understanding the presence and levels of Noratropine in biological samples can help in determining the safety and potential risks associated with Atropine exposure.
Used in Quality Control and Analysis:
In the pharmaceutical and chemical industries, Noratropine can be used as a reference compound for quality control and analytical purposes. It can help in the development of accurate and reliable methods for the detection, quantification, and characterization of Atropine and its metabolites in various samples.

InChI:InChI=1/C16H21NO3/c18-9-15(16(19)20)11-3-1-2-10(6-11)12-7-13-4-5-14(8-12)17-13/h1-3,6,12-15,17-18H,4-5,7-9H2,(H,19,20)

Upstream product

• 64-17-5 ethanol 
• 537-29-1 norhyoscyamine 
• 51-55-8 Atropine 
• 149423-39-2 tropoyl chloride 
• 14383-51-8 (endo)-8-Azabicyclo[3.2.1]octan-3-ol Hydrochloride 
• 5908-99-6 atropine sulfate 
• 529-64-6 Tropic acid 
• 4574-60-1 atropine-N-oxide hydrochloride 

Downstream Products

• 51-55-8 atropine 
• 51-55-8 Atropine 
• 22235-81-0 (1R,3R,5S)-3'-hydroxy-2'-phenylpropionic acid 8-isopropyl-8-azabicyclo[3.2.1]oct-3-yl ester 
• 119293-48-0 N-formyl-noratropine 

Relevant articles and documents

Preparation of noratropine by oxidative n-demethylation of atropine

-

MEANS AND METHODS FOR THE N-DEALKYLATION OF AMINES

The invention relates to improved means and methods for N- dealkylation of alkylated amines. Provided is a method for the catalytic N- dealkylation of an N-alkylated amine substrate, comprising incubating said amine substrate in a suitable solvent in the

Studies on the oxidative N-demethylation of atropine, thebaine and oxycodone using a FeIII-TAML catalyst

The reaction pathway and selectivity of the oxidative N-demethylation of the alkaloid atropine with H2O2 using a Fe III-TAML catalyst has been investigated. The conversion of atropine in ethanol with aqueous H2O

Synthesis and radiolabelling of ipratropium and tiotropium for use as PET ligands in the study of inhaled drug deposition

Ipratropium bromide [(1R,3r,5S,8r,2′RS)-3-(3′-hydroxy-2′- phenylpropionyloxy)-8-isopropyl-8-methyl-8-aza-bicyclo[3.2.1]octan-8-ium bromide] and tiotropium bromide [(1R,2R,4S,5S,7s)-7-[2′-hydroxy-2′, 2′-di(thiophen2″-yl)acetoxy]-9,9-dimethyl-9-aza-3-oxatricyclo[3.3.1. 02,4]nonan-9-ium bromide] are inhaled drugs used in the treatment of chronic obstructive pulmonary disease (COPD) and asthma. Tertiary amine precursors have been synthesized and radiolabelled with carbon-11 by N-alkylation with [11C]CH3I. The [11C] ipratropium and [11C]tiotropium positron emission tomography (PET) ligands are obtained with high radiochemical purity, in 0.3 and 0.5% non-decay corrected yields based on [11C]CO2 at end-of-synthesis and specific activities of 11 and 18 GBq μ mol-1, respectively, calculated at end-of-synthesis. These PET radioligands can be used in the study of inhaled drug deposition. CSIRO 2006.